Biomarker · Gene alteration
FGFR3 alteration (mutation or fusion)
Activating FGFR3 point mutations or fusions detected by sequencing of tumor tissue; used as a predictive marker for FGFR inhibitors in urothelial carcinoma.
CI-BIO-00000025FGFR3graph →NCIt C150618
Also calledFGFR3 mutation · FGFR3 fusion · FGFR3-TACC3 · S249C
Derived
Associated cancers (9)
Cancers mapped in ACCEPTED CIViC predictive, prognostic or diagnostic items whose variant (molecular markers) or gene (gene-level markers) is in this biomarker's scope. Counts by type and native level; each row links to the cancer's evidence tab.
| Cancer | Items | Predictive | Prognostic | Diagnostic | Levels A / B / C / D / E |
|---|---|---|---|---|---|
| Malignant Neoplasm | 6 | 6 | — | — | 0 / 0 / 0 / 6 / 0 |
| Bladder Carcinoma | 3 | 2 | — | 1 | 0 / 2 / 0 / 1 / 0 |
| Transitional Cell Carcinoma | 3 | 3 | — | — | 1 / 0 / 1 / 1 / 0 |
| Malignant Bladder Neoplasm | 2 | 2 | — | — | 0 / 1 / 0 / 1 / 0 |
| Urothelial Carcinoma |
Derived
Drugs with predictive evidence (12)
Therapies named in in-scope PREDICTIVE CIViC items, plus targets of PREDICTS_RESPONSE_TO knowledge edges from in-scope variants. Sensitivity and resistance are counted separately and never merged into a verdict.
| Drug | CIViC items | Sensitivity | Resistance | Best level | Edges (S / R) | Cancer context |
|---|---|---|---|---|---|---|
| ErdafitinibSmall Molecule | 6 | 3 | 3 | A | 3 / 5 | Malignant Bladder Neoplasm, Malignant Neoplasm, Malignant Ovarian Brenner Tumor, Transitional Cell Carcinoma +1 |
| R3Mab | 5 | 1 | 4 |
Curated evidence
Predictive evidence items (19)
ACCEPTED CIViC predictive items in scope, grouped by molecular profile and therapy with native level, direction and cancer context. 50 per page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 21119661
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| FGFR3 Overexpression2 | ||||||||
| Dovitinib + | ||||||||
Regulatory
Approvals mentioning the linked drugs (94)
Approval records of the derived drug set, plus records whose indication text names this biomarker. Each record names its authority, jurisdiction, indication text and status — a drug approved in one jurisdiction for one indication is not 'approved' in general, and an approval listed here is not necessarily restricted to this biomarker.
- Source
- Health Canada — Drug Product Database (DPD)
- Dataset
- Health Canada DPD
- Version
- dpd-2026-09-11
- Retrieved
- Sep 11, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- regulatory
- License
- Open Government Licence – Canada (https://open.canada.ca/en/open-government-licence-canada)
- Run
- ING-HEALTHCANADADPD-20260911-000001
Clinical trials
Active trials (84)
Trials with an active ClinicalTrials.gov status, an intervention mapped to a derived drug and a condition mapped to an associated cancer. 36 recruiting · 24 active phase 3 · 445 in any status. Most recently updated first, 50 per page.
- Source
- ClinicalTrials.gov
- Dataset
- ClinicalTrials.gov API v2 studies
- Retrieved
- Sep 30, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02465060 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | active not recruiting | Phase 2 |
Literature
Linked publications (36)
Publications linked to the scope gene(s) through PubMed entity edges; 25 per page, newest first.
- Source
- PubMed (NLM)
- Dataset
- PubMed E-utilities
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)